ICOTYDE maintains high skin clearance rates through two years in plaque psoriasis

Johnson & Johnson has reported new two-year Phase III data showing sustained skin clearance and symptom improvement with ICOTYDE, also known as icotrokinra, in adults and adolescents with moderate-to-severe plaque psoriasis.

The findings come from the ICONIC-LEAD study and were presented at the 2026 Fall Clinical Dermatology meeting.

ICOTYDE is an oral peptide designed to selectively block the interleukin 23 receptor and is being developed for patients aged 12 years and older with plaque psoriasis.

At week 112, high levels of skin clearance were maintained among patients receiving ICOTYDE.

From week 64 through week 112, at least 72% of patients achieved a 90% improvement in Psoriasis Area and Severity Index, known as PASI 90.

Over the same period, at least 70% achieved clear or almost clear skin based on an Investigator’s Global Assessment score of zero or one.

Complete skin clearance was also maintained over the longer term.

At least 44% of patients achieved PASI 100 from week 64 through week 112, while at least 46% reached an Investigator’s Global Assessment score of zero, indicating completely clear skin.

Patient reported improvements in itch were also sustained.

Johnson & Johnson said 78% of patients maintained clinically meaningful improvement in itch between weeks 64 and 112.

The study also assessed patients who had responded to treatment but were later withdrawn from ICOTYDE.

Among patients who had achieved PASI 90 before treatment withdrawal at week 24, 85% regained their PASI 90 response within 24 weeks after restarting therapy.

Mark Lebwohl, MD, Professor and Chair Emeritus of Dermatology at the Icahn School of Medicine at Mount Sinai and an ICONIC-LEAD investigator, said long-term disease control is an important consideration when selecting treatment for chronic plaque psoriasis.

He said the two-year findings demonstrate durable skin clearance while maintaining a consistent safety profile.

Safety results through week 112 remained in line with the established profile of ICOTYDE.

No new safety signals were identified during the extended follow-up period.

David M. Lee, MD, PhD, Global Immunology Therapeutic Area Head at Johnson & Johnson, said the long-term findings further support the use of targeted oral treatment for patients requiring ongoing management of plaque psoriasis.

The latest results add to the broader ICONIC clinical programme evaluating ICOTYDE across different plaque psoriasis populations and disease presentations.

---

---

Related Topics and Keywords

adolescents, adults, Biopharma, clinical trials, dermatology, Fall Clinical 2026, ICONIC-LEAD, Icotrokinra, ICOTYDE, IL 23 receptor, Immunology, itch, Johnson and Johnson, oral peptide, PASI 100, PASI 90, pharma news, phase III, Plaque Psoriasis, psoriasis, skin clearance